Postmenopausal women with weight loss have a reduced risk for breast cancer.
Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or metastatic breast cancer (N=431) to receive talazoparib 1mg or physician's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).
Higher Levels of Anti-CA15.3 and Anti-CA125 Linked to Increased Risk for Mucinous Epithelial Ovarian CancerOctober 12, 2018
Researchers used the EPIC Cohort to identify whether anti-CA125 and anti-CA15.3 antibodies alone or in combination with antigens may determine epithelial ovarian cancer risk.
Among cancer survivors, illness perception may affect patient health-related quality of life and mortality.
Although ovarian cancer risk may be reduced with regular use of low-dose aspirin, the use of nonaspirin analgesics may increase the risk of ovarian cancer among long-term, high-quantity users.
Stool burden can be a particularly challenging aspect of colonoscopies, making potentially cancerous lesions easier to miss.
Weight loss may indicate a cancer diagnosis in patients presenting in primary care, specifically when weight loss correlates to another cancer-related clinical feature.
82 percent of variant carriers identified in exome sequencing had not undergone prior testing.
Women with ovarian or endometrial cancer who adhere to a ketogenic diet may benefit from a selective loss of fat mass and a reduction in fasting serum insulin, while still retaining lean mass.
Almost 43% of those presenting to NCI center for second opinion have change in diagnosis.
Barriers found among PCPs in surveillance of HCC indicate the need for clinical interventions, including provider education.
Talazoparib, a poly(adenosine diphosphate-ribose) inhibitor, may significantly enhance progression-free survival in patients with advanced breast cancer and a germline BRCA1/2 mutation.
Combined hormonal contraception use tied to lower risk; risk down with increasing duration of use.
The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.
For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.
The North American Menopause Society has found that postmenopausal women with a breast cancer diagnosis may have vitamin D deficiency as well as higher rates of obesity.
Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.
Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian CancerSeptember 10, 2018
Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.
Odds of choosing screening up for men with family history, African descent, low socioeconomic status.
Although endocrine therapy following surgery is recommended for HR-positive/HER2-negative, axillary node-negative breast cancers, the value of adjuvant chemotherapy in the setting of moderate risk is unclear.
No increased risk of cancer recurrence among RA patients initiating tumor necrosis factor inhibitor treatment.
Cytology recommended every 3 years from age 21; different screening options from age 30 to 65.
Few differences between rural, urban patients in cancer outcomes with uniform access to cancer care.
A Phase 1 study in healthy volunteers showed a favorable safety profile with no serious adverse events.
Lumpectomy, radiotherapy tied to reduction in breast cancer mortality vs lumpectomy, mastectomy.
In high-volume centers, patients with liver metastases from colorectal cancer may often be eligible for minimally invasive liver surgery via laparoscopy, thereby reducing potential morbidity risks associated with open surgery.
For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.
High-dose esomeprazole taken in combination with aspirin may safely and effectively improve outcomes in patients with Barrett esophagus.
Studies conducted in people have mixed results, with some indication of increased risk of ovarian cancer.
Ribociclib approved in combo with AI as endocrine tx for HR-positive, HER2-negative advanced breast CA.